Nautilus Biotechnology, Inc.

NAUT Nasdaq SEC CIK 1808805
Follow Nautilus Biotechnology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $234K
Net income −$15.6M −15.2% vs same quarter last year
EPS, diluted −$0.12 −9.1% vs same quarter last year
Operating cash flow −$13.3M −20.4% vs same quarter last year
Revenue by quarter
$0
$0
$190K
$234K
Q2 25 Q3 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$59M
FY24−$70.8M
FY23−$63.7M
FY22−$57.9M
FY21−$50.3M
FY20−$15.6M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$52M
FY24−$61.3M
FY23−$54.2M
FY22−$48.1M
FY21−$41.5M
FY20−$14.9M
FY19-